Report cover image

Relapsing Remitting Multiple Sclerosis Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20147035

Description

In the United States, around 1 million people are living with multiple sclerosis. Out of these, 80-85% of people diagnosed with multiple sclerosis have relapsing-remitting multiple sclerosis, making it the most common sub-type. Therefore, researchers are emphasizing on developing high-quality and potent drugs to manage the disease effectively.

Report Coverage

The Relapsing Remitting Multiple Sclerosis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into relapsing remitting multiple sclerosis drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for relapsing remitting multiple sclerosis. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The relapsing remitting multiple sclerosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from relapsing remitting multiple sclerosis.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing relapsing remitting multiple sclerosis product development activities related to relapsing remitting multiple sclerosis.

Relapsing Remitting Multiple Sclerosis Drug Pipeline Outlook

Relapsing-remitting multiple sclerosis (RRMS) is a type of multiple sclerosis. Multiple sclerosis is an autoimmune disorder that affects the central nervous system. It causes the immune system to attack the insulation protection on the nerves called myelin, leading to difficulties in passing signals. With relapsing-remitting multiple sclerosis, an individual witnesses flare-ups or remissions. It is the most common type of multiple sclerosis. Most individuals diagnosed with the disease start with RRMS.

There are different treatment alternatives available to treat the diseases. These work by slowing down disease progression and reducing inflammation. The route of administration can be oral, or infusion based.

Relapsing Remitting Multiple Sclerosis – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of relapsing remitting multiple sclerosis drug candidates based on several segmentations including:

By Phase

EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class

EMR’s relapsing remitting multiple sclerosis therapeutic assessment report covers 50+ drug analyses based on drug classes:
  • Immunomodulators
  • Oral Disease-Modifying Therapies
  • Monoclonal Antibodies
  • Selective Adhesion Molecule Inhibitors
  • Immunosuppressants
By Route of Administration

EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
  • Oral
  • Parenteral
  • Others
Relapsing Remitting Multiple Sclerosis – Pipeline Assessment Segmentation, By Phases 

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for relapsing remitting multiple sclerosis. There are around 142 drugs in phase II of relapsing remitting multiple sclerosis drugs.

Relapsing Remitting Multiple Sclerosis – Pipeline Assessment Segmentation, By Drug Classes 

The drug molecule categories covered under relapsing remitting multiple sclerosis pipeline analysis include immunomodulators, oral disease-modifying therapies, monoclonal antibodies, selective adhesion molecule inhibitors and immunosuppressants. The choice of treatment depends on the stage of the disease, patient allergies, and multiple factors.

Relapsing Remitting Multiple Sclerosis Clinical Trials Therapeutic Assessment – Competitive Dynamics 

The EMR report for the relapsing remitting multiple sclerosis drug insights covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in relapsing remitting multiple sclerosis clinical trials:
  • Celgene
  • Hoffmann-La Roche
  • Hikma Pharmaceuticals LLC
  • Biogen
  • Merck KGaA
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Novartis Pharmaceuticals
  • Bayer
  • Eli Lilly and Company
Relapsing Remitting Multiple Sclerosis – Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for spinal fusion. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of spinal fusion drug candidates.

ANK-700

This drug is under investigation for its safety and tolerability against relapsing remitting multiple sclerosis in adults. Sponsored by Anokion SA, the Phase 1 study is divided into 2 arms, wherein the patients in part A receive a single dose of the drug while the patients in part B will either receive 3 doses of ANK-700 or placebo.

Ocrelizumab

Roche is conducting a Phase 3 randomised, double-blind, multicenter study to examine the efficacy and safety of the drug in comparison to finglomod taken orally. Ocrelizumab will be intravenously administered every 24 weeks to children as well as adolescents (aged between 10-18 years) affected with relapsing-remitting multiple sclerosis.

IMCY-0141

Sponsored by Imcyse SA, this experimental drug is in Phase 1 for treating relapsing-remitting multiple sclerosis. Based on a new mechanism, it is part of an interventional study that has 150 participants.

Reasons To Buy This Report

The Relapsing Remitting Multiple Sclerosis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for relapsing remitting multiple sclerosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into  relapsing remitting multiple sclerosis collaborations, regulatory environments, and potential growth opportunities within relapsing remitting multiple sclerosis pipeline insights.

Key Questions Answered in the Relapsing Remitting Multiple Sclerosis – Pipeline Insight Report
  • Which companies/institutions are leading the relapsing remitting multiple sclerosis development?
  • What is the efficacy and safety profile of spinal fusion pipeline drugs?
  • Which company is leading the relapsing remitting multiple sclerosis pipeline development activities?
  • What is the current relapsing remitting multiple sclerosis commercial assessment?
  • What are the opportunities and challenges present in the relapsing remitting multiple sclerosis drug pipeline landscape?
  • What is the efficacy and safety profile of relapsing remitting multiple sclerosis pipeline drugs?
  • Which company is conducting major trials for relapsing remitting multiple sclerosis drugs?
  • Which companies/institutions are involved in relapsing remitting multiple sclerosis collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in spinal fusion?
Related Reports

Global Multiple Sclerosis Treatment Market Global Clinical Trials Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions
2 Executive Summary
3 Overview of Relapsing Remitting Multiple Sclerosis
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Relapsing Remitting Multiple Sclerosis: Epidemiology Snapshot
5.1 Relapsing Remitting Multiple Sclerosis Incidence by Key Markets
5.2 Relapsing Remitting Multiple Sclerosis– Patients Seeking Treatment in Key Markets
6 Relapsing Remitting Multiple Sclerosis: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Relapsing Remitting Multiple Sclerosis: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Relapsing Remitting Multiple Sclerosis, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Relapsing Remitting Multiple Sclerosis Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Relapsing Remitting Multiple Sclerosis Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 BG00012
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Ocrelizumab
10.2.3 Other Drugs
11 Relapsing Remitting Multiple Sclerosis Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 BAF312
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Natalizumab
11.2.3 Other Drugs
12 Relapsing Remitting Multiple Sclerosis Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 ANK-700
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 IMCY-0141
12.2.3 Other Drugs
13 Relapsing Remitting Multiple Sclerosis Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Drug 2
13.2.3 Other Drugs
14 Relapsing Remitting Multiple Sclerosis, Key Drug Pipeline Companies
14.1 Celgene
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 GlaxoSmithKline
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Novartis Pharmaceuticals
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Bristol-Myers Squibb
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Biogen
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Hikma Pharmaceuticals LLC
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Merck KGaA
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
14.8 Eli Lilly and Company
14.8.1 Company Snapshot
14.8.2 Pipeline Product Portfolio
14.8.3 Financial Analysis
14.8.4 Recent News and Developments
14.9 Hoffmann-La Roche
14.9.1 Company Snapshot
14.9.2 Pipeline Product Portfolio
14.9.3 Financial Analysis
14.9.4 Recent News and Developments
14.10 Bayer
14.10.1 Company Snapshot
14.10.2 Pipeline Product Portfolio
14.10.3 Financial Analysis
14.10.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us